Brief: Pharmaust Says To Undertake Phase 2 Study In Covid-19 Rather Than A Phase 1 Study
24/05/2022 24:07
May 24 (Reuters) - Pharmaust Ltd PAA.AX :
* TO UNDERTAKE A PHASE 2 STUDY IN COVID-19 RATHER THAN A
PHASE 1
STUDY
Source text for Eikon: ID:nASXbJXvMr
Further company coverage: PAA.AX
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO